INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Incyte Corporation
Incyte Corporation
Janssen Research & Development, LLC
MEI Pharma, Inc.
Fate Therapeutics
TG Therapeutics, Inc.
SecuraBio
Gilead Sciences
Aptevo Therapeutics